论文部分内容阅读
32例慢性乙型肝炎接受导向干扰素(含国产α-干扰素100万单位与乙肝病毒单克隆抗体交联组成)治疗,对照组25例采用干扰素(每支含基因工程干扰素。α-2b 300万单位)治疗,用药次数和疗程相同。结果,乙肝导向干扰素治疗组32例临床治愈22例,治愈率为68.75％,好转8例,好转率为25％,总有效率为93.75％。对照组25例治愈、好转分别为10例和6例,治愈、好转率分别为40％和28％,总有效率为64％。差异显著(P<0.01)。HBV-M变化情况,治疗组HBsAg治疗后阴转4例(12.5％),HBeAg阴转21例(65.6％),抗-HBe阳转16例(50％),HBV-DNA阴转20例(62.5％)。对照组治疗后HBsAg阴转1例(25％),HBeAg阴转12例(48％),抗-HBe阳转8例(32％),HBV-DNA阴转10例(40％),乙肝导向干扰素治疗组优于干扰素对照组(P<0.05或0.01)。
32 cases of chronic hepatitis B received guided interferon (containing 1 million domestic α-interferon and hepatitis B virus monoclonal antibody cross-linked composition), the control group of 25 patients with interferon (each containing genetically engineered interferon alpha- 2b 3000000 units) treatment, medication and treatment the same number of times. Results, 32 cases of hepatitis B-interferon treatment group cured 22 cases, the cure rate was 68.75%, improved in 8 cases, the improvement rate was 25%, the total effective rate was 93.75%. The control group of 25 patients were cured, improvement were 10 cases and 6 cases, cure, improvement rates were 40% and 28%, the total effective rate was 64%. The difference was significant (P <0.01). The changes of HBV-M in treatment group were as follows: 4 cases (12.5%) were negative after HBsAg treatment, 21 cases (65.6%) were HBeAg negative, 16 cases were anti-HBe positive 62.5%). In the control group, HBsAg was negative in 1 case (25%), HBeAg negative in 12 cases (48%), anti-HBe positive in 8 cases (32%) and HBV DNA negative in 10 cases Interferon treatment group than interferon control group (P <0.05 or 0.01).